{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:24:49Z","timestamp":1787289889909,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K12AR084228"],"award-info":[{"award-number":["K12AR084228"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.gore.2026.102178","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:50:02Z","timestamp":1785945002000},"page":"102178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trends in estrogen replacement therapy use among younger gynecologic cancer survivors, 2013-2021"],"prefix":"10.1016","volume":"66","author":[{"given":"Christine Hsu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyn","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Adekanmbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao N.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey B.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.gore.2026.102178_bb0005","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.gore.2026.102178_bb0010","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvag082","article-title":"Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications","volume":"10","author":"Boretti","year":"2026","journal-title":"J. Endocr. Soc."},{"issue":"9","key":"10.1016\/j.gore.2026.102178_bb0015","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/medicina55090602","article-title":"The controversial history of hormone replacement therapy","volume":"55","author":"Cagnacci","year":"2019","journal-title":"Medicina (Mex)"},{"key":"10.1016\/j.gore.2026.102178_bb0020","series-title":"Advances Women\u2019s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy","author":"Commissioner O of the. HHS","year":"2025"},{"issue":"4","key":"10.1016\/j.gore.2026.102178_bb0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric J. Int. Menopause Soc."},{"issue":"3","key":"10.1016\/j.gore.2026.102178_bb0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11864-025-01298-5","article-title":"Updates in hormone replacement therapy for survivors of gynecologic cancers","volume":"26","author":"Gorman","year":"2025","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102178_bb0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03009734.2018.1544597","article-title":"Gynecologists are afraid of prescribing hormone replacement to endometrial\/ovarian cancer survivors despite national guidelines\u2014a survey in Sweden","volume":"123","author":"Halldorsdottir","year":"2018","journal-title":"Ups. J. Med. Sci."},{"issue":"10430","key":"10.1016\/j.gore.2026.102178_bb0040","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","article-title":"Managing menopause after cancer","volume":"403","author":"Hickey","year":"2024","journal-title":"Lancet"},{"issue":"10382","key":"10.1016\/j.gore.2026.102178_bb0050","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.gore.2026.102178_bb0055","author":"Merative"},{"issue":"1","key":"10.1016\/j.gore.2026.102178_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ijgc-2021-002949","article-title":"Employment disruption among women with gynecologic cancers","volume":"32","author":"Nitecki","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102178_bb0065","series-title":"Estrogen HRT use is Rising: Real-World Trends","author":"Research T","year":"2026"},{"issue":"2","key":"10.1016\/j.gore.2026.102178_bb0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","volume":"157","author":"Sinno","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102178_bb0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ygyno.2023.11.010","article-title":"Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer","volume":"180","author":"Suzuki","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102178_bb0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/gme.0b013e3181f43404","article-title":"Trends in menopausal hormone therapy use of U.S. office-based physicians, 2000-2009","volume":"18","author":"Tsai","year":"2011","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.gore.2026.102178_bb0085","first-page":"4","article-title":"Insights into perimenopause: a survey of perceptions, opinions on treatment, and potential approaches","volume":"5","author":"Wegrzynowicz","year":"2025","journal-title":"Women Basel Switz"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892600158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892600158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:49:35Z","timestamp":1787287775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235257892600158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"alternative-id":["S235257892600158X"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102178","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in estrogen replacement therapy use among younger gynecologic cancer survivors, 2013-2021","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102178"}}